42 results about "Mouse Colon" patented technology

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention discloses preparation of a methoxyl derivative and application of the methoxyl derivative in pharmacy. The methoxy derivative as shown in the formula I has good anti-tumor activity, and the anti-tumor effect is effectively achieved through the growth inhibition and killing effect on tumor cells. The methoxyl derivative not only can inhibit the growth of CT26 transplanted tumors, but also can promote the activation and infiltration of lymphocytes in an in-vivo tumor microenvironment. Meanwhile, the compound also has a remarkable inhibiting effect on the growth of mouse colon cancer CT26 cell strains in vitro.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The invention discloses an antigen expression vector, a combination of the antigen expression vector and an antibody and application of the combination in cancer treatment. The antigen expression vector comprises one or more DMP-antigen coding gene units; the DMP-antigen coding gene is composed of two functional elements DMP and an antigen coding gene, the DMP is an NF-kappa B specific promoter, and the antigen coding gene is an antigen molecule coding sequence. The antigen expression vector prepared by the invention can selectively express antigen molecules in cancer cells, an in-vivo delivery vector taking adeno-associated virus as the antigen expression vector, and a combination of an antigen CD20 expressed by the antigen expression vector and an anti-CD20 antibody rituximab. The compound has a good treatment effect on mouse colon cancer on mice and human colon cancer on humanized mice, and has good tumor targeting property and safety in the treatment of the cancer mice. The invention is expected to provide a new technology and a new reagent for the treatment of various cancer diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The present application relates to the technical field of microorganism, and particularly relates to a luohanguo flavor dairy product and a preparation method and application thereof, the present application adopts buffalo milk, luohanguo powder, paracasei and rhamnosus to prepare the flavor dairy product, it is found during the preparation process research that the luohanguo powder, paracasei and rhamnosus have good synergies, the luohanguo powder fermented dairy product prepared by the combination has good antioxidant function, through animal experiment, the product can effectively relieve the inflammation of DSS-induced mouse colon, and the effect of the luohanguo flavor fermented milk is close to that of positive drug, so the product is a good diet therapy product.

The invention provides a construction method of engineered lactic acid bacteria for constitutive expression of SodA protein and application of the engineered lactic acid bacteria in treatment of IBD. The invention provides a construction method of engineered lactic acid bacteria (KI (at) lSodA) for relieving IBD (Infectious Bronchitis Disease) constitutive expression SodA protein. A verification experiment result shows that the KI (at) lSodA highly expresses the SodA protein, and the oxidative stress management capability of the strain is improved; meanwhile, the KI (at) lSodA also has long-term use safety, the treatment of the KI (at) lSodA remarkably relieves the colitis symptoms and in-vivo inflammation conditions of mice in an acute stage, a recovery stage and a chronic state, and the KI (at) lSodA shows a strong intestinal microbial diversity recovery capability in all three experimental models, and particularly shows a remarkable repair effect in a recovery stage model. Therefore, the invention provides a new basis for IBD treatment.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

The invention relates to the technical field of biological medicine, and discloses dual-network hydrogel for treating inflammatory bowel disease as well as a preparation method and application of the dual-network hydrogel. The preparation method of the double-network hydrogel comprises the following steps: dissolving glycyrrhizic acid into deionized water, and then adding beta-lactoglobulin to obtain a solution A; dissolving zinc chloride and 2, 3, 4-trihydroxybenzoic acid in deionized water to obtain a solution B; mixing the solution A and the solution B in proportion, and stirring for reaction to obtain the double-network hydrogel. A main framework of the double-network hydrogel is composed of a first-stage network formed by glycyrrhizic acid and zinc ions through self-crosslinking and a second-stage network formed by beta-lactoglobulin and 2, 3, 4-trihydroxybenzoic acid through Schiff base and hydrogen bond crosslinking. The invention provides the dual-crosslinked hydrogel with the skeleton being a therapeutic effective component and good plasticity and adhesion, and the dual-crosslinked hydrogel has the advantages of resistance to external severe environment and strong anti-inflammatory ability, and can effectively relieve mouse colitis.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

Through virtual screening based on molecular docking, molecular dynamics simulation, free energy calculation and experimental verification, it is found for the first time that benfotiamine can efficiently antagonize P2Y14R, and the IC50 value of benfotiamine reaches 0.31 nM. Experimental results show that benfotiamine can significantly relieve inflammatory reactions of a DSS-induced mouse colitis model and an MSU-induced gouty arthritis model, and the action mechanism of benfotiamine is closely related to inhibition of activation of NLRP3 inflammasomes. Benfotiamine is used as a vitamin B1 derivative clinically applied for a long time and has good safety and tolerance. The invention provides a brand new pharmacological action target and indication direction, realizes new use of old medicines, is beneficial to shortening the research and development period of medicines and reducing the development cost, and has important application prospects and economic and social values in the field of treatment of inflammatory diseases.

The application discloses a kind of composite microecological preparation and preparation method and application, belong to microbial technical field.The composite microecological preparation is core-shell structure, the core-shell structure is divided into inside and shell layer, inside includes Bifidobacterium adolescentis, shell layer includes metal polyphenol network and ficoll polysaccharide;The metal polyphenol network includes the complex coating formed by pterostilbene and calcium ion.The core is BA, the shell is made of FCPS, PTE, Ca 2+ Network composition, can protect Bifidobacterium adolescentis to reach intestine successfully and colonize, directly inhibit inflammatory response, and relieve CDI-induced mouse colitis and oxidative stress damage by regulating intestinal flora, indole and the generation of indole derivatives, solve the pain point that traditional microecological preparation probiotic survival rate is low, poor targeting, limited effect.

The invention belongs to the technical field of biological medicine, and particularly relates to safflower seed meal protein and peptide as well as a preparation method and application thereof. The safflower seed meal protein and peptide provided by the invention are prepared through the steps of degreasing, alkali extraction, ultrasonic-assisted extraction, acid precipitation, ammonium sulfate precipitation, enzymolysis and the like, and have good antioxidant activity. Animal experiments show that the protein and the peptide can effectively relieve DSS-induced mouse colitis, remarkably improve hematochezia, diarrhea, colon shortening and other symptoms, regulate immune organ indexes and T lymphocyte subgroups and enhance the oxidation resistance of intestinal tracts, and do not show toxicity under high dosage. The traditional Chinese medicine composition can be effectively used for preparing a medicine for treating colitis, and a natural and safe new candidate medicine is provided for colitis treatment.

The invention relates to the technical field of biological medicines, and particularly discloses a drug-resistant cell line MC38-IR for immunotherapy of mouse colon cancer as well as a preparation method and application of the drug-resistant cell line MC38-IR. The cell line is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: C2025358. Experimental results show that the MC38-IR cell line has a remarkable PD-1 antibody drug resistance characteristic while maintaining the in-vitro proliferation and migration capabilities of parent cells. An in-vivo experiment shows that the tumor volume of a mouse inoculated with the cell line is not obviously inhibited after PD-1 antibody treatment, the lifetime has no statistical difference compared with that of a control group, and the parent MC38 cell shows obvious treatment response. The invention solves the problem of lack of colon cancer immunotherapy drug resistance models in the prior art, provides an important tool for researching drug resistance mechanisms, screening reverse drug resistance drugs and developing combined treatment strategies, and has higher scientific research and clinical application values.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The application discloses an enteral nutritional composition, comprising an enteral nutritional suspension and inulin. In a mouse colon anastomosis model, 2 mg / kg of lipopolysaccharide (LPS) is injected intraperitoneally 24 hours before the operation to establish a systemic inflammation preconditioning background, and enteral nutritional intervention containing inulin is given after the operation. The experimental results show that, compared with the enteral nutritional suspension without the addition of inulin, the enteral nutritional composition containing inulin can improve postoperative recovery, improve the mechanical strength of the anastomotic stoma, reduce local inflammation cell infiltration of the anastomotic stoma, enhance local tissue proliferation activity and reduce cell apoptosis, promote the macrophage phenotype to deviate to the repair direction, and be accompanied by adjustment of tissue adhesion bacterial community structure and increase of butyric acid level. The application provides a clear composition and implementable technical solution for early postoperative nutritional support under the background of high risk of inflammation.

The invention is applicable to the technical field of microorganisms, and provides a lactobacillus paracasei Jlu-CH9 and application thereof, the lactobacillus paracasei Jlu-CH9 is preserved in China General Microbiological Culture Collection Center on January 4, 2026, the preservation number is CGMCC No.37281, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain Jlu-CH9 obtained by separation has certain tolerance to acid and cholate, has no hemolysis phenomenon, and is sensitive to various antibiotics; the compound has good inhibitory activity on dipeptidyl peptidase IV and has a certain potential of reducing blood sugar. The compound has relatively good inhibitory activity on a plurality of pathogenic bacteria including salmonella typhimurium, staphylococcus aureus, escherichia coli, clostridium perfringens and pseudomonas aeruginosa; the traditional Chinese medicine composition has good prevention and treatment effects on a DSS-induced mouse colitis model, and can repair intestinal barriers, regulate immune balance, remodel intestinal flora homeostasis and relieve colonic atrophy.

The invention discloses application of a small molecule compound in preparation of a pyroptosis inhibitor. The chemical name of the small molecule compound is isopropyl-2-(2, 2-dichloroacetamido)-5-(diethylaminoformyl)-4-methylthiophene-3-carboxylic acid diethyl ester, and the short name is C9. The pyroptosis model capable of highly simulating the in-vivo environment is constructed based on the human cell line and the mouse primary cells, and the model can accurately reflect the biological change of the cells in the pyroptosis process. Through multiple rounds of screening and verification, C9 is excellent in performance in a test and shows excellent pyroptosis inhibition performance. Through MST and SPR experiments, good affinity and high specificity between the C9 and the target protein are determined. Finally, a disease model proves that C9 can effectively relieve key pathological injury and inflammatory response of mouse acute sepsis and mouse colitis.

The application of a Clematis glauca pectin in the preparation of food with anti-inflammatory effect belongs to the technical field of food processing and health care. The Clematis glauca pectin is obtained by ultrasonic-assisted enzyme extraction and column chromatography purification with Clematis glauca pericarp as raw material. Experiments show that the pectin has significant DPPH free radical, ABTS free radical scavenging capacity and Fe 3+ reducing capacity, and good antioxidant activity. In a DSS-induced mouse colitis model, the pectin can significantly reduce DAI, improve colon shortening, reduce the levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-17A) in serum and colon tissue, repair colon mucosal damage, and regulate intestinal flora structure, such as increasing the relative abundance of beneficial bacteria such as Bacteroides and Akkermansia. The present application provides a new way for developing new anti-inflammatory functional food or health care products for assisting the conditioning of colitis.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The invention belongs to the field of medicine and health, and particularly relates to cationic egg white peptide hydrogel as well as a preparation method and application thereof. Specifically, fresh egg white is taken as a raw material, cationic egg white peptide is obtained through enzymolysis, ultrafiltration, nanofiltration and freeze drying, and carboxymethyl chitosan, sodium alginate, anhydrous calcium chloride and the cationic egg white peptide are compounded to construct the cationic egg white peptide hydrogel system. The cationic egg white peptide can be effectively cross-linked with a hydrogel matrix to form a stable hydrogel system, has a function of repairing a damaged intestinal barrier, and can be used for remarkably relieving symptoms such as disappearance of a colon tissue crypt structure, reduction of the number of goblet cells, inflammatory factor infiltration and the like caused by intestinal barrier damage; meanwhile, the proinflammatory factor level in the colon tissue of the mouse is reduced, and the anti-inflammatory factor level is improved. A new thought is provided for construction of an egg white peptide targeted delivery system, and a new view angle is provided for development of functional food applied to repair of damaged intestinal barriers.

The application provides use of an S1PR1 biased agonist in preparation of a drug for treating inflammatory bowel disease. The application proves through animal tests that, compared with a dextran sodium sulfate treated inflammatory bowel disease model group of mice, the colon length of mice added with SAR247799 treatment tends to be normalized, and finally the purpose of treating inflammatory bowel disease is achieved, and the application has a practical popularization and application prospect.

The invention discloses a new bacterium CML367 of Trichothrix erysipelas and application thereof, and belongs to the technical field of microorganisms. The CML367 is preserved in the China General Microbiological Culture Collection Center on August 6, 2025, and the preservation number of the CML367 is CGMCC (China General Microbiological Culture Collection Center) No. 35535. CML367 treatment can delay adverse effects such as weight loss and disease activity score increase of the mouse caused by DSS treatment, and the disease activity score of the mouse can be remarkably reduced; the trend that the colon length of the mouse is reduced can be relieved, and meanwhile, the colon pathological score of the mouse can be remarkably reduced. Therefore, the invention provides a new strain of erysipelothrix sp., and the new strain has a wide application prospect.

The invention discloses application of valeriana jatamansi jones. The valeriana jatamansi jones are derived from dry roots and rhizomes of valeriana jatamansi jones, and the valeriana jatamansi jones can regulate cell balance of CD4 < + > helper T cells in a human immune system so as to relieve colon tissue pathological damage and mucoprotein secretion abnormality. The traditional Chinese medicine composition can protect the colon tissue pathological injury and mucous membrane layer of the UC mouse, repair the colon pathological injury, regulate and control the balance of intestinal immune cells, and is high in safety coefficient.

The application discloses a bifidobacterium that can significantly improve the expression of BDNF of a host and an application thereof, and belongs to the technical field of microorganisms. The bifidobacterium CCFM1359 provided by the application can effectively improve the levels of BDNF and its specific receptor TrkB in the colon of a mouse, can also increase the number of enteric glial cells, improve the content of excitatory neurotransmitter Ach in the colon, down-regulate the content of inhibitory neurotransmitter NO, and repair the enteric nervous system. Moreover, the bacteria can down-regulate the gene expression levels of TLR2 and TNF-alpha, up-regulate the gene expression level of IL-10, reduce the inflammation level in the colon, and regulate the intestinal motility. Therefore, in the future, a more personalized treatment scheme can be adopted for patients with damaged enteric nerves (including but not limited to intestinal motility disorders), and the application prospect is very considerable.

The invention discloses application of intestinal bacteroides and metabolites thereof in treatment of colitis, and belongs to the field of microorganisms. The name of the bacterial strain is Bacteroides intestinae SCAUTCVM001, and the preservation number of the bacterial strain is GDMCC No: 67454. The invention further discloses a preparation method of the bacterial strain. The intestinal bacteroides SCAUTCVM001 disclosed by the invention can be used for metabolizing tryptophan (Trp) and indole-3-acetic acid (IAA) in vivo and in vitro to generate metabolites of yellow uric acid (Xa) and indole-3-formaldehyde (ICA); the mouse colitis can be relieved. Therefore, the intestinal bacteroides and the metabolite of the intestinal bacteroides can relieve mouse colitis, increase expression of colon ZO1 and IgA and treat mouse colitis.

The invention relates to the technical field of probiotic microcapsules, and particularly discloses a targeted adhesion mixed polysaccharide probiotic freeze-dried microcapsule capable of enhancing an anti-inflammatory effect and application. The bifidobacterium animalis subsp. Lactis BA-9 is used as a core material, a mixed solution of sulfydryl polygonatum polysaccharide sT-PP-2 and yak milk sialic acid oligosaccharide YM-l2 is used as a composite wall material, and a protective agent is added to obtain the microcapsule. The composite wall material has the triple effects of targeting, adhesion and anti-inflammation, the probiotic embedding rate is 86.14%, the viable bacterial loading rate is 78.03%, the survival rate of the composite wall material stored at 4 DEG C for 28 days is 90.03% + / -0.93%, and large-scale colonization of the colons of the mice can be realized in 24 hours. And aiming at DSS-induced ulcerative colitis mice, the traditional Chinese medicine composition can reduce the colon malondialdehyde by 36.4% and the myeloperoxidase activity by 53.7%, and regulate inflammatory factors. The preparation method is simple and convenient and can be used for functional food and intestinal inflammation auxiliary treatment drugs.

The invention provides an antibody specifically binding to human CCR8 or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof provided by the invention can be bound to the surface of a cell expressing CCR8 to block the binding of CCL1-CCR8, and can kill Treg through ADCC, and meanwhile, the antibody or the antigen binding fragment thereof has antitumor activity in a mouse MC38 colon cancer model.